Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.
Hospital Charle Nicolle, Tunis, Tunis BAB SOUIKA, Tunisia
William Beaumont Hospital, Royal Oak, Michigan, United States
Monash Medical Centre, Southern Health, Melbourne, Victoria, Australia
Prince of Wales Hospital, Sydney, New South Wales, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
1160.19.43001 A.ö. Krankenhaus d. Statutarstadt Wiener Neustadt, Wr. Neustadt, Austria
1160.19.42006 Hospital Mlada Boleslav, Mlada Boleslav, Czech Republic
1160.19.32005 Virga Jesseziekenhuis, Gent, Belgium
Clinic for Radiology and Nuclear Medicine, Magdeburg, Sachsen-Anhalt, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.